Connor, Clark & Lunn Investment Management Ltd. Chemo Centryx, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

  • $18.8 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 02, 2018
SELL
$10.62 - $13.98 $602,568 - $793,211
-56,739 Closed
0 $0
Q1 2018

May 14, 2018
SELL
$5.9 - $14.99 $45,784 - $116,322
-7,760 Reduced 12.03%
56,739 $772,000
Q4 2017

Feb 09, 2018
SELL
$5.53 - $8.42 $7,056 - $10,743
-1,276 Reduced 1.94%
64,499 $384,000
Q3 2017

Nov 14, 2017
SELL
$6.5 - $10.69 $131,950 - $217,007
-20,300 Reduced 23.58%
65,775 $488,000
Q2 2017

Aug 14, 2017
BUY
N/A
86,075
86,075 $806,000

Others Institutions Holding CCXI

# of Institutions
6
Shares Held
66.3K
Call Options Held
0
Put Options Held
0
View Full List

About ChemoCentryx, Inc.

CCXI Quotes by TradingView
  • Ticker CCXI
  • Exchange NASDAQ
  • Shares Outstandng 71,919,696
  • Market Cap $3.68M
  • Description
  • ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...
More about CCXI
Track This Portfolio

Track Connor, Clark & Lunn Investment Management Ltd. Portfolio

Follow Connor, Clark & Lunn Investment Management Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email